1. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.
- Author
-
Pimpinelli, Fulvia, Marchesi, Francesco, Piaggio, Giulia, Giannarelli, Diana, Papa, Elena, Falcucci, Paolo, Spadea, Antonio, Pontone, Martina, Di Martino, Simona, Laquintana, Valentina, La Malfa, Antonia, Di Domenico, Enea Gino, Di Bella, Ornella, Falzone, Gianluca, Ensoli, Fabrizio, Vujovic, Branka, Morrone, Aldo, Ciliberto, Gennaro, and Mengarelli, Andrea
- Subjects
- *
POLYCYTHEMIA vera , *VACCINE effectiveness , *MYELOFIBROSIS , *THROMBOCYTOSIS , *RUXOLITINIB - Abstract
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF